actually quarter was fine-it was the guidance (lower and belowQ1 fiasco?
We need President Trump to come in and drain the swamp!
Maybe he can take the VP of sales job after he gets kicked out of the Oval...
What is the trial that led to that "superiority" claim was bogus and manufactured? What if the FDA was " Hoodwinked?" Would that matter?
I don't think the claim is holding up in the real world...thus, the reason for my questions
I heard they are going back to distributors with some W2 rep coverage. Is anyone seeing this product? It just has not been anywhere in my area yet.
Who's taking the over/under on Nevro reporting $80 million in Q2?
Putting that # into perspective, consider the date they launched. Then consider the amount of business they've taken from MDT, Bos and us. Pretty scary actually. Looks like data don't lie! Outcomes and Clinical Data trumps whatever short term mgmt. issues they might have.
$75 today!
$64-what happened to my options?
$64-what happened to my options?
so Nevro sales were up substantially, 35% 3rd qtr vs last year. So who took the big hit, stj, mdt. bsx or "all the above"? Which other company reported a bump of 35% + growth? Turnover, who gives a crap! Open VP position, who gives a crap.
